Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer
Merck shares closed down 0.03% at $119.28 after the FDA approved a Keytruda-based regimen for certain platinum-resistant ovarian cancer patients. The stock had reached $121.62 earlier in the session. Merck also announced new bladder and kidney cancer data to be presented at ASCO GU later this month. Chief Marketing Officer Chirfi Guindo sold 10,000 shares at an average price of $121.46.